145 related articles for article (PubMed ID: 31251693)
1. Reply to E. Hindié et al.
Connolly RM; Huang CY; Stearns V; Wahl RL
J Clin Oncol; 2019 Aug; 37(23):2092-2093. PubMed ID: 31251693
[No Abstract] [Full Text] [Related]
2. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Bonneterre ME; Bonneterre J
Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
[No Abstract] [Full Text] [Related]
3. Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association".
Poletto E; Martel S; Lambertini M; Puglisi F
Breast; 2018 Jun; 39():151-152. PubMed ID: 29555407
[No Abstract] [Full Text] [Related]
4. Reply to E. Hindié and A.K. Goel et al.
Holtschmidt J; Kuemmel S; Krug D; Breit E; Kuehn T; Reinisch M
J Clin Oncol; 2019 Oct; 37(29):2705-2707. PubMed ID: 31465263
[No Abstract] [Full Text] [Related]
5. Reply to the letter by Takeshi Yamada et al. concerning "Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?".
Zhou J; Peng Z; Shen L
J Gastroenterol; 2016 May; 51(5):508. PubMed ID: 26897738
[No Abstract] [Full Text] [Related]
6. Reply to T.J.A. Dekker.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Oct; 38(28):3351-3352. PubMed ID: 32658630
[No Abstract] [Full Text] [Related]
7. Reply to A. Ocana et al.
Cortés J; Llombart-Cussac A; Calvo E
J Clin Oncol; 2013 Mar; 31(9):1253-4. PubMed ID: 23616989
[No Abstract] [Full Text] [Related]
8. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).
Umemura S; Sakamoto G; Sasano H; Tsuda H; Akiyama F; Kurosumi M; Tokuda Y; Watanabe T; Toi M; Hasegawa T; Osamura RY
Breast Cancer; 2001; 8(4):316-20. PubMed ID: 11791124
[TBL] [Abstract][Full Text] [Related]
9. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
Sendur MA; Aksoy S; Altundag K
Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
[No Abstract] [Full Text] [Related]
11. Reply to A. Oguz et al.
O'Sullivan CC; Holmes E; Campbell C; Bradbury I; Zujewski JA; Gelber RD
J Clin Oncol; 2016 Feb; 34(6):640-1. PubMed ID: 26644531
[No Abstract] [Full Text] [Related]
12. Reply to D. Serraino et al.
Partridge AH; Gelber S; Gelber R
J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323031
[No Abstract] [Full Text] [Related]
13. Mechanisms of trastuzumab resistance in breast cancer.
Tolaney SM; Krop IE
Anticancer Agents Med Chem; 2009 Mar; 9(3):348-55. PubMed ID: 19275526
[TBL] [Abstract][Full Text] [Related]
14. [Trastuzumab treatment for breast cancer].
Yamashiro H; Toyama K; Bando H; Saji S; Toi M
Nihon Rinsho; 2004 Jul; 62(7):1305-11. PubMed ID: 15283148
[TBL] [Abstract][Full Text] [Related]
15. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials.
Hortobagyi GN; Perez EA
Semin Oncol; 2001 Oct; 28(5 Suppl 16):41-6. PubMed ID: 11706395
[TBL] [Abstract][Full Text] [Related]
16. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
17. Reply to a. Avan et Al.
Baselga J; Clark E; Kiermaier A; Swain SM
J Clin Oncol; 2015 May; 33(15):1712. PubMed ID: 25870094
[No Abstract] [Full Text] [Related]
18. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
19. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
20. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.
Molenaar RJ; Sidana S; Radivoyevitch T; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
J Clin Oncol; 2018 Jun; 36(18):1889-1892. PubMed ID: 29723096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
